BCTX — Briacell Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Briacell Enters Definitive Arrangement Agreement For Spin Out Of Briapro Therapeutics Corp.
Brief: BriaCell Announces $4 Million Strategic Investment And Clinical Alliance With Prevail Partners, LLC And Prevail Infoworks, Inc.
Brief: Briacell Presents Positive Data Demonstrating Survival And Clinical Benefits In Advanced Metastatic Breast Cancer At The 2023 Aacr
Brief: Briacell Announces To Spin-Out Certain Pre-Clinical Assets Into Spinco
Verb Technology plunges 50% on pricing stock offering
Verb Technology falls on plans to raise equity
Brief: BriaCell Therapeutics Corp Has Approved Measures To Address "Alleged Illegal Trading" Activity Of Its Publicly Traded Securities
Brief: BriaCell Announces Positive End Of Phase II Meeting With The FDA
Brief: Briacell Therapeutics Corp Announces New Patent Issuance, Bria-Ots IND Timing Guidance, And Additional Clinical Sites To Boost Enrolment
Brief: Briacell Announces Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer At 2022 San Antonio Breast Cancer Symposium
Brief: Ipa’S Subsidiary Biostrand And Briacell Announce Artificial Intelligence Collaboration And License Agreement To Discover And Develop Anti-Cancer Antibodies
Brief: Briacell Therapeutics In Discussions With FDA To Advance To Its Pivotal Study, Move Forward With Registration Study Along Path To FDA Approval
Brief: Briacell Announces Successful Completion Of Phase I Portion Of Clinical Study In Advanced Breast Cancer
Brief: BriaCell Partners With Caris Life Sciences To Expand Patient Outreach, Molecular Profiling
Brief: BriaCell Secures License For A Promising Novel Anti-Cancer Agent
Brief: BriaCell Partners With Waisman Biomanufacturing To Manufacture And Supply Prostate Cancer Immunotherapy
Brief: Briacell Therapeutics Corp - Adds Additional Clinical Sites To Broaden Patient Access And Further Boost Enrollment
BriaCell rises on FDA 'fast track' tag for cancer therapy
Brief: BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy